-
1
-
-
0842281551
-
Principles of protein folding, misfolding and aggregation
-
Dobson, C. Principles of protein folding, misfolding and aggregation. Semin. Cell Develop. Biol. 2004, 15, 3-16.
-
(2004)
Semin. Cell Develop. Biol.
, vol.15
, pp. 3-16
-
-
Dobson, C.1
-
2
-
-
84892408458
-
Mechanisms of protein-folding diseases at a glance
-
Valastyan, J.S.; Lindquist, S. Mechanisms of protein-folding diseases at a glance. Dis. Model. Mechan. 2014, 7, 9-14.
-
(2014)
Dis. Model. Mechan.
, vol.7
, pp. 9-14
-
-
Valastyan, J.S.1
Lindquist, S.2
-
3
-
-
46749117136
-
Molecular and cellular aspects of protein misfolding and disease
-
Herczenik, E.; Gebbink, M.F.B.G. Molecular and cellular aspects of protein misfolding and disease. FASEB J. 2008, 22, 2115-2133.
-
(2008)
FASEB J.
, vol.22
, pp. 2115-2133
-
-
Herczenik, E.1
Gebbink, M.F.B.G.2
-
4
-
-
84892921640
-
Structure of an early native-like intermediate of b2-microglobulin amyloidogenesis
-
Vanderhaegen, S.; Fislage, M.; Domanska, K.; Versees, W.; Pardon, E.; Bellotti, V.; Steyaert, J. Structure of an early native-like intermediate of b2-microglobulin amyloidogenesis. Protein Sci. 2013, 22, 1349-1357.
-
(2013)
Protein Sci.
, vol.22
, pp. 1349-1357
-
-
Vanderhaegen, S.1
Fislage, M.2
Domanska, K.3
Versees, W.4
Pardon, E.5
Bellotti, V.6
Steyaert, J.7
-
5
-
-
0037135111
-
The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
-
Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
-
(2002)
Science
, vol.297
, pp. 353-356
-
-
Hardy, J.1
Selkoe, D.J.2
-
6
-
-
70349705441
-
Prions: Protein aggregation and infectious diseases
-
Aguzzi, A.; Calela, A.M. Prions: Protein aggregation and infectious diseases. Physiol. Rev. 2009, 89, 1105-1152.
-
(2009)
Physiol. Rev.
, vol.89
, pp. 1105-1152
-
-
Aguzzi, A.1
Calela, A.M.2
-
7
-
-
77649202326
-
Protein aggregation diseases: Pathogenicity and therapeutic perspectives
-
Aguzzi, A.; O'Connor, T. Protein aggregation diseases: Pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 2010, 9, 237-248.
-
(2010)
Nat. Rev. Drug Discov.
, vol.9
, pp. 237-248
-
-
Aguzzi, A.1
O'Connor, T.2
-
8
-
-
84871414210
-
The many faces of α-synuclein: From structure and toxicity to therapeutic target
-
Lashuel, H.A.; Overk, C.R.; Oueslati, A.; Masliah, E. The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nature 2013, 14, 38-42.
-
(2013)
Nature
, vol.14
, pp. 38-42
-
-
Lashuel, H.A.1
Overk, C.R.2
Oueslati, A.3
Masliah, E.4
-
9
-
-
83455202793
-
α-Synuclein misfolding and Parkinson's disease
-
Breydo, L.; Wu, J.W.; Uversky, V.N. α-Synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 2012, 1822, 261-285.
-
(2012)
Biochim. Biophys. Acta
, vol.1822
, pp. 261-285
-
-
Breydo, L.1
Wu, J.W.2
Uversky, V.N.3
-
10
-
-
84880730823
-
Huntington's disease: Underlying molecular mechanisms and emerging concepts
-
Labbadia, J.; Morimoto, R.I. Huntington's disease: Underlying molecular mechanisms and emerging concepts. Trends Biochem. Sci. 2013, 38, 378-385.
-
(2013)
Trends Biochem. Sci.
, vol.38
, pp. 378-385
-
-
Labbadia, J.1
Morimoto, R.I.2
-
11
-
-
84957935046
-
-
Alzheimer's association. (accessed on 28 December 2014)
-
Alzheimer's association. Alzheimer's Disease and Dementia. Available online: http://www.alz.org (accessed on 28 December 2014).
-
Alzheimer's Disease and Dementia.
-
-
-
12
-
-
27844445619
-
Acetylcholinasterase inhibitors for the treatment of dementia in Alzheimer's disease: Do we need ne inhibitors?
-
Small, D.H. Acetylcholinasterase inhibitors for the treatment of dementia in Alzheimer's disease: Do we need ne inhibitors? Exp. Opin. Emerg. Drugs 2005, 10, 817-825.
-
(2005)
Exp. Opin. Emerg. Drugs
, vol.10
, pp. 817-825
-
-
Small, D.H.1
-
13
-
-
68649126582
-
Targets for neuroprotection in Parkinson's disease
-
Yacoubian, T.A.; Standaert, D.G. Targets for neuroprotection in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792, 676-687.
-
(2009)
Biochim. Biophys. Acta
, vol.1792
, pp. 676-687
-
-
Yacoubian, T.A.1
Standaert, D.G.2
-
14
-
-
19744378296
-
Levodopa and the progression of Parkinson's disease
-
Fahn, S.; Oakes, D.; Shoulson, I.; Kieburtz, K.; Rudolph, A.; Lang, A.; Olanow, C.W.; Tanner, C.; Marek, K. Levodopa and the progression of Parkinson's disease. N. Eng. J. Med. 2004, 351, 2498-2508.
-
(2004)
N. Eng. J. Med.
, vol.351
, pp. 2498-2508
-
-
Fahn, S.1
Oakes, D.2
Shoulson, I.3
Kieburtz, K.4
Rudolph, A.5
Lang, A.6
Olanow, C.W.7
Tanner, C.8
Marek, K.9
-
15
-
-
84858374665
-
The amyloid state of proteins in human diseases
-
Eisenberg, D.; Jucker, M. The amyloid state of proteins in human diseases. Cell 2012, 148, 1188-1203.
-
(2012)
Cell
, vol.148
, pp. 1188-1203
-
-
Eisenberg, D.1
Jucker, M.2
-
16
-
-
84875871051
-
Atomic structure and hierarchical assembly of a cross-β amyloid fibril
-
Fitzpatrick, A.W.P.; Debelouchina, G.T.; Bayro, M.J.; Clare, D.K.; Caporini, M.A.; Bajaj, V.S.; Jaroniec, C.P.; Wang, L.; Ladizhansky, V.; Müller, S.A.; et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proc. Natl. Acad. Sci. USA 2013, 110, 5468-5473.
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 5468-5473
-
-
Fitzpatrick, A.W.P.1
Debelouchina, G.T.2
Bayro, M.J.3
Clare, D.K.4
Caporini, M.A.5
Bajaj, V.S.6
Jaroniec, C.P.7
Wang, L.8
Ladizhansky, V.9
Müller, S.A.10
-
17
-
-
33847662852
-
Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid s-peptide
-
Haas, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid s-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8, 101-112.
-
(2007)
Nat. Rev. Mol. Cell Biol.
, vol.8
, pp. 101-112
-
-
Haas, C.1
Selkoe, D.J.2
-
18
-
-
84877254025
-
Possitive anti-amyloid immunotheraphy in Alzheimer's disease: What are the most promising targets?
-
Moreth, J.; Mavoungou, C.; Schindowski, K. Possitive anti-amyloid immunotheraphy in Alzheimer's disease: What are the most promising targets? Immun. Ageing 2013, 10, 18-27.
-
(2013)
Immun. Ageing
, vol.10
, pp. 18-27
-
-
Moreth, J.1
Mavoungou, C.2
Schindowski, K.3
-
19
-
-
84857642949
-
The toxic A11oligomer and Alzheimer's disease: An emperor in need of clothes
-
Benilova, I.; Karran, E.; De Strooper, B. The toxic A11oligomer and Alzheimer's disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349-357.
-
(2012)
Nat. Neurosci.
, vol.15
, pp. 349-357
-
-
Benilova, I.1
Karran, E.2
De Strooper, B.3
-
20
-
-
36749078121
-
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers
-
Kayed, R.; Head, E.; Sarsoza, F.; Saing, T.; Cotman, C.W.; Necula, M.; Margol, L.; Wu, J.; Breydo, L.; Thompson, J.L.; et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegen. 2007, 2, 18-29.
-
(2007)
Mol. Neurodegen.
, vol.2
, pp. 18-29
-
-
Kayed, R.1
Head, E.2
Sarsoza, F.3
Saing, T.4
Cotman, C.W.5
Necula, M.6
Margol, L.7
Wu, J.8
Breydo, L.9
Thompson, J.L.10
-
21
-
-
84864502830
-
Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment
-
Morgado, I.; Wieligman, K.; Bereza, M.; Rönicke, R.; Meinhardt, K.; Annamalai, K.; Baumann, M.; Wacker, J.; Hortschansky, P.; Malešević, M.; et al. Molecular basis of β-amyloid oligomer recognition with a conformational antibody fragment. Proc. Natl. Acad. Sci. USA 2012, 109, 12503-12508.
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 12503-12508
-
-
Morgado, I.1
Wieligman, K.2
Bereza, M.3
Rönicke, R.4
Meinhardt, K.5
Annamalai, K.6
Baumann, M.7
Wacker, J.8
Hortschansky, P.9
Malešević, M.10
-
22
-
-
84855987854
-
Structure-based design of conformation- and sequence-specific antibodies against amyloid a
-
Perchiacca, J.M.; Reza, A.; Ladiwala, A.; Bhattacharya, M.; Tessier, P.M. Structure-based design of conformation- and sequence-specific antibodies against amyloid a. Proc. Natl. Acad. Sci. USA 2012, 109, 84-89.
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 84-89
-
-
Perchiacca, J.M.1
Reza, A.2
Ladiwala, A.3
Bhattacharya, M.4
Tessier, P.M.5
-
23
-
-
84879554975
-
Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages
-
Guilliams, T.; El-Turk, F.; Buell, A.K.; O'Day, E.M.; Aprile, F.A.; Esbjörner, E.K.; Vendruscolo, M.; Cremades, N.; Pardon, E.; Wyns, L.; et al. Nanobodies raised against monomeric α-synuclein distinguish between fibrils at different maturation stages. J. Mol. Biol. 2013, 425, 2397-2411.
-
(2013)
J. Mol. Biol.
, vol.425
, pp. 2397-2411
-
-
Guilliams, T.1
El-Turk, F.2
Buell, A.K.3
O'Day, E.M.4
Aprile, F.A.5
Esbjörner, E.K.6
Vendruscolo, M.7
Cremades, N.8
Pardon, E.9
Wyns, L.10
-
24
-
-
37649019187
-
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ profibrils
-
Habicht, G.; Haupt, C.; Friedrich, R.P.; Hortschansky, P.; Sachse, C.; Meinhardt, J.; Wieligmann, K.; Gellerman, G.P.; Brodhun, M.; Götz, J.; et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ profibrils. Proc. Natl. Acad. Sci. USA 2007, 104, 19232-19237.
-
(2007)
Proc. Natl. Acad. Sci. USA
, vol.104
, pp. 19232-19237
-
-
Habicht, G.1
Haupt, C.2
Friedrich, R.P.3
Hortschansky, P.4
Sachse, C.5
Meinhardt, J.6
Wieligmann, K.7
Gellerman, G.P.8
Brodhun, M.9
Götz, J.10
-
25
-
-
0030058382
-
Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer 83-amyloid peptide
-
Salomon, B.; Koppel, R.; Hanan, E.; Katzav, T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer 83-amyloid peptide. Proc. Natl. Acad. Sci. USA 1995, 93, 452-455.
-
(1995)
Proc. Natl. Acad. Sci. USA
, vol.93
, pp. 452-455
-
-
Salomon, B.1
Koppel, R.2
Hanan, E.3
Katzav, T.4
-
26
-
-
84858720343
-
Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
-
Weggen, S.; Beher, D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res. Ther. 2012, 4, 9.
-
(2012)
Alzheimers Res. Ther
, vol.4
, pp. 9
-
-
Weggen, S.1
Beher, D.2
-
27
-
-
0022744803
-
Abnormal phosphorylation of the microtubule associated protein (tau) in Alzheimer cytoskeletal pathology
-
Grundke-Iqbal, I.; Iqbal, K.; Tung, Y.C.; Quinlan, M.; Wisniewski, H.M.; Binder, L.I. Abnormal phosphorylation of the microtubule associated protein (tau) in Alzheimer cytoskeletal pathology, Proc. Natl. Acad. Sci. USA 1986, 93, 4913-4917.
-
(1986)
Proc. Natl. Acad. Sci. USA
, vol.93
, pp. 4913-4917
-
-
Grundke-Iqbal, I.1
Iqbal, K.2
Tung, Y.C.3
Quinlan, M.4
Wisniewski, H.M.5
Binder, L.I.6
-
28
-
-
0030005625
-
Tau protein and the neurofibrillary pathology of Alzheimer's disease
-
Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann. NY Acad. Sci. 1996, 777, 121-131.
-
(1996)
Ann. NY Acad. Sci.
, vol.777
, pp. 121-131
-
-
Goedert, M.1
-
29
-
-
13844275951
-
Mean age of onset in familial Alzheimer's disease is determined by amyloid beta42
-
Duering, M.; Grimm, M.O.; Grimm, H.S.; Schroder, J.; Hartmann, T. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta42. Neurobiol. Aging 2005, 26,785-788.
-
(2005)
Neurobiol. Aging
, vol.26
, pp. 785-788
-
-
Duering, M.1
Grimm, M.O.2
Grimm, H.S.3
Schroder, J.4
Hartmann, T.5
-
30
-
-
78149488153
-
Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis
-
Pimplikar, S.W.; Nixon, R.A.; Robakis, N.K.; Shen, J.; Tsai, L. Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis. J. Neurosci. 2010, 30, 14946-14954.
-
(2010)
J. Neurosci.
, vol.30
, pp. 14946-14954
-
-
Pimplikar, S.W.1
Nixon, R.A.2
Robakis, N.K.3
Shen, J.4
Tsai, L.5
-
31
-
-
20944448555
-
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
-
Gilman, S.; Koller. M.; Black, R.; Jenkins, L.; Griffith, S.; Fox, N.; Eisner, L.; Kirby, L.; Rovira, M.; Forette, F.; et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64, 1553-1562.
-
(2005)
Neurology
, vol.64
, pp. 1553-1562
-
-
Gilman, S.1
Koller, M.2
Black, R.3
Jenkins, L.4
Griffith, S.5
Fox, N.6
Eisner, L.7
Kirby, L.8
Rovira, M.9
Forette, F.10
-
32
-
-
0037393454
-
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report
-
Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P., Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat. Med. 2003, 9, 448-452.
-
(2003)
Nat. Med.
, vol.9
, pp. 448-452
-
-
Nicoll, J.A.1
Wilkinson, D.2
Holmes, C.3
Steart, P.4
Markham, H.5
Weller, R.O.6
-
33
-
-
64549152492
-
Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders
-
Vellas, B.; Black, R.; Thal, L.J.; Fox, N.C.; Daniels, M.; McLennan, G.; Tompkins, C.; Leibman, C.; Pomfret, M.; Grundman, M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 2009, 6,144-151.
-
(2009)
Curr. Alzheimer Res.
, vol.6
, pp. 144-151
-
-
Vellas, B.1
Black, R.2
Thal, L.J.3
Fox, N.C.4
Daniels, M.5
McLennan, G.6
Tompkins, C.7
Leibman, C.8
Pomfret, M.9
Grundman, M.10
-
34
-
-
84874330804
-
Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation
-
Miles, L.A.; Crespi, G.A.N.; Doughty, L.; Parker, M.W. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Nat. Sci. Rep. 2013, 3, 1303.
-
(2013)
Nat. Sci. Rep.
, vol.3
, pp. 1303
-
-
Miles, L.A.1
Crespi, G.A.N.2
Doughty, L.3
Parker, M.W.4
-
35
-
-
37849012608
-
Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDPAPP mouse
-
Seubert, P.; Barbour, R.; Khan, K.; Motter, R.; Tang, P.; Kholodenko, D.; Kling, K.; Schenk, D.; Johnson-Wood, K.; Schroeter, S.; et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDPAPP mouse. Neurodegener. Dis. 2008, 5, 65-71.
-
(2008)
Neurodegener. Dis.
, vol.5
, pp. 65-71
-
-
Seubert, P.1
Barbour, R.2
Khan, K.3
Motter, R.4
Tang, P.5
Kholodenko, D.6
Kling, K.7
Schenk, D.8
Johnson-Wood, K.9
Schroeter, S.10
-
36
-
-
80054752317
-
Molecular basis for amyloid-beta polymorphism
-
Colletier, J.P.; Laganowsky, A.; Landau, M.; Zhao, M.; Soriaga, A.B.; Goldschmidt, L.; Flot, D.; Cascio, D.; Sawaya, M.R.; Eisengerg, D. Molecular basis for amyloid-beta polymorphism. Proc. Natl. Acad. Sci. USA 2011, 108, 16938-16943.
-
(2011)
Proc. Natl. Acad. Sci. USA
, vol.108
, pp. 16938-16943
-
-
Colletier, J.P.1
Laganowsky, A.2
Landau, M.3
Zhao, M.4
Soriaga, A.B.5
Goldschmidt, L.6
Flot, D.7
Cascio, D.8
Sawaya, M.R.9
Eisengerg, D.10
-
37
-
-
84862777153
-
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: A retrospective analysis
-
Sperling, R.; Salloway, S.; Brooks, D.J.; Tampieri, D.; Barakos, J.; Fox, N.C.; Raskind, M.; Sabbagh, M.; Honig, L.S.; Porsteinsson, A.P.; et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012, 11, 241-249.
-
(2012)
Lancet Neurol.
, vol.11
, pp. 241-249
-
-
Sperling, R.1
Salloway, S.2
Brooks, D.J.3
Tampieri, D.4
Barakos, J.5
Fox, N.C.6
Raskind, M.7
Sabbagh, M.8
Honig, L.S.9
Porsteinsson, A.P.10
-
38
-
-
84855780598
-
Gantenerumab: A novel human anti-AGGantibody demonstrates sustained vertebral amyloid-ddbinding and elicits cell-mediated removal of human amyloid-a
-
Bohrmann, B.; Baumann, K.; Benz, J.; Gerber, F.; Huber, W.; Knoflach, F.; Messer, J.; Oroszlan, K.; Rauchenberger, R; Richter, W.F.; et al. Gantenerumab: A novel human anti-AGGantibody demonstrates sustained vertebral amyloid-ddbinding and elicits cell-mediated removal of human amyloid-a. J. Alzheimer's Dis. 2012, 28, 49-69.
-
(2012)
J. Alzheimer's Dis.
, vol.28
, pp. 49-69
-
-
Bohrmann, B.1
Baumann, K.2
Benz, J.3
Gerber, F.4
Huber, W.5
Knoflach, F.6
Messer, J.7
Oroszlan, K.8
Rauchenberger, R.9
Richter, W.F.10
-
39
-
-
85117465579
-
-
End of the RoAD for Gantenerumab? (accessed on 27 June 2015)
-
End of the RoAD for Gantenerumab? Roche Declares Prodromal Alzheimer's Trial Futile. Available online: http://www.alzforum.org/news/research-news/end-road-gantenerumab-rochedeclares- prodromal-alzheimers-trial-futile (accessed on 27 June 2015).
-
Roche Declares Prodromal Alzheimer's Trial Futile.
-
-
-
40
-
-
84886937126
-
Immunotherapy for Alzheimer's disease: Hoops and hurdles
-
Lemere, C.A. Immunotherapy for Alzheimer's disease: Hoops and hurdles. Mol. Neurodegener. 2013, 8, 36-42.
-
(2013)
Mol. Neurodegener.
, vol.8
, pp. 36-42
-
-
Lemere, C.A.1
-
41
-
-
84865529158
-
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
-
Bateman, R.J.; Xiong, C.; Benzinger, T.L.; Fagan A.M.; Goate, A.; Fox, N.C.; Marcus, D.S.; Cairns, N.J.; Xie, X.; Blazey, T.M.; et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367, 795-804.
-
(2012)
N. Engl. J. Med.
, vol.367
, pp. 795-804
-
-
Bateman, R.J.1
Xiong, C.2
Benzinger, T.L.3
Fagan, A.M.4
Goate, A.5
Fox, N.C.6
Marcus, D.S.7
Cairns, N.J.8
Xie, X.9
Blazey, T.M.10
-
42
-
-
75849124774
-
-
(accessed on 27 June 2015)
-
Clinical Trials. Available online: www.clinicalcrials.gov (accessed on 27 June 2015).
-
Clinical Trials.
-
-
-
43
-
-
0029078972
-
Correlations of synaptic and pathological markers with cognition of the eldery
-
Dickson, D.W.; Chrystal, H.A.; Bevona, C.; Honer, W.; Vincent, I.; Davis, P. Correlations of synaptic and pathological markers with cognition of the eldery. Neurobiol. Aging 1995, 16, 285-298.
-
(1995)
Neurobiol. Aging
, vol.16
, pp. 285-298
-
-
Dickson, D.W.1
Chrystal, H.A.2
Bevona, C.3
Honer, W.4
Vincent, I.5
Davis, P.6
-
44
-
-
0038117796
-
Correlation between elevated levels if amyloid C-peptide in the brain and cognitive decline
-
Naslund, J.; Haroutunian, V.; Mohs, R.; Davis, K.L.; Davis, P.; Greengard, P.; Buxbaum, J. Correlation between elevated levels if amyloid C-peptide in the brain and cognitive decline. JAMA 2000, 283, 1571-1577.
-
(2000)
JAMA
, vol.283
, pp. 1571-1577
-
-
Naslund, J.1
Haroutunian, V.2
Mohs, R.3
Davis, K.L.4
Davis, P.5
Greengard, P.6
Buxbaum, J.7
-
45
-
-
0026756887
-
Methological variables in the assessment of 4-amyloid neurotoxicity
-
Busciglio, J.; Lorenzo, A.; Yankner, B. Methological variables in the assessment of 4-amyloid neurotoxicity. Neurobiol. Aging 1992, 13, 609-612.
-
(1992)
Neurobiol. Aging
, vol.13
, pp. 609-612
-
-
Busciglio, J.1
Lorenzo, A.2
Yankner, B.3
-
46
-
-
84858984601
-
Unravelling the early events of amyloid-44Protein (Ar) aggregation: Techniques for the determination of Aaaaggregate size
-
Pryor, N.E.; Moss, M.A.; Hestekin, C.N. Unravelling the early events of amyloid-44Protein (Ar) aggregation: Techniques for the determination of Aaaaggregate size. Int. J. Mol. Sci. 2012, 13, 3038-3072.
-
(2012)
Int. J. Mol. Sci.
, vol.13
, pp. 3038-3072
-
-
Pryor, N.E.1
Moss, M.A.2
Hestekin, C.N.3
-
47
-
-
79951761390
-
The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: Oligomer size or conformation?
-
Broersen, K.; Rousseau, F.; Schymkowitz, J. The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation? Alzheimer's Res. Ther. 2010, 2, 12.
-
(2010)
Alzheimer's Res. Ther.
, vol.2
, pp. 12
-
-
Broersen, K.1
Rousseau, F.2
Schymkowitz, J.3
-
48
-
-
57649148788
-
Structural classification of toxic amyloid oligomers
-
Glabe, C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283, 29639-29643.
-
(2008)
J. Biol. Chem.
, vol.283
, pp. 29639-29643
-
-
Glabe, C.G.1
-
49
-
-
79251567055
-
Crystal structure of the amyloid-βp3 fragment provides a model for oligomer formation in Alzheimer's disease
-
Streltsov, V.A.; Varghese, J.N.; Masters, C.L.; Nuttall, S.D. Crystal structure of the amyloid-βp3 fragment provides a model for oligomer formation in Alzheimer's disease. J. Neurosci. 2011, 31, 1419-1426.
-
(2011)
J. Neurosci.
, vol.31
, pp. 1419-1426
-
-
Streltsov, V.A.1
Varghese, J.N.2
Masters, C.L.3
Nuttall, S.D.4
-
50
-
-
56249092747
-
Anti-oligomeric Aβ single chain variable domain antibody blocks Aβ-induced toxicity against human neuroblastoma cells
-
Zameer, A.; Kasturirangan, S.; Emadi, S.; Nimmagadda, S.V.; Sierks, M.R. Anti-oligomeric Aβ single chain variable domain antibody blocks Aβ-induced toxicity against human neuroblastoma cells. J. Mol. Biol. 2008, 384, 917-928.
-
(2008)
J. Mol. Biol.
, vol.384
, pp. 917-928
-
-
Zameer, A.1
Kasturirangan, S.2
Emadi, S.3
Nimmagadda, S.V.4
Sierks, M.R.5
-
51
-
-
58249104047
-
Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation
-
Lafaye, P.; Achour, I.; England, P.; Duyckaerts, C.; Rougeon, F. Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation. Mol. Immunol. 2009, 46, 695-704.
-
(2009)
Mol. Immunol.
, vol.46
, pp. 695-704
-
-
Lafaye, P.1
Achour, I.2
England, P.3
Duyckaerts, C.4
Rougeon, F.5
-
52
-
-
84861185114
-
Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form
-
Kasturirangan S.; Li, L.; Emadi, S.; Boddapati, S.; Schulz, P.; Sierks, M.R. Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form. Neurobiol. Aging 2012, 33, 1320-1328.
-
(2012)
Neurobiol. Aging
, vol.33
, pp. 1320-1328
-
-
Kasturirangan, S.1
Li, L.2
Emadi, S.3
Boddapati, S.4
Schulz, P.5
Sierks, M.R.6
-
53
-
-
0242668337
-
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
-
Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300, 486-489.
-
(2003)
Science
, vol.300
, pp. 486-489
-
-
Kayed, R.1
Head, E.2
Thompson, J.L.3
McIntire, T.M.4
Milton, S.C.5
Cotman, C.W.6
Glabe, C.G.7
-
54
-
-
84863693043
-
An effector-reduced anti- β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ
-
Adolfsson, O.; Pihlgren, M.; Toni, N.; Varisco, Y.; Buccarello, A.L.; Antoniello, K.; Lohmann, S.; Piorkowska, K.; Gafner, V.; Arwal, J.K.; et al. An effector-reduced anti- β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J. Neurosci. 2012, 32, 9677-9689.
-
(2012)
J. Neurosci.
, vol.32
, pp. 9677-9689
-
-
Adolfsson, O.1
Pihlgren, M.2
Toni, N.3
Varisco, Y.4
Buccarello, A.L.5
Antoniello, K.6
Lohmann, S.7
Piorkowska, K.8
Gafner, V.9
Arwal, J.K.10
-
55
-
-
84879030439
-
Molecular characterisation and preclinical efficacy
-
Dunstan, R.; Bussiere, T.; Rhodes, K.; Engber, T.; Maier, M.; Weinreb, P.; Grimm, J.; Nitsch, R.; Arustu, M.; Qian, F.; et al. Molecular characterisation and preclinical efficacy. Alzheimer's Dement. 2011, 7, S457.
-
(2011)
Alzheimer's Dement.
, vol.7
-
-
Dunstan, R.1
Bussiere, T.2
Rhodes, K.3
Engber, T.4
Maier, M.5
Weinreb, P.6
Grimm, J.7
Nitsch, R.8
Arustu, M.9
Qian, F.10
-
56
-
-
84879025530
-
Restoration of home cage activity in Tg2576 mice by immunotherapy with the Ab-oligomer selective antibody A-887755
-
Relo, A.; Barghorn, S.; Ebert, U.; Hillen, H.; Gross, G.; Schoemaker, H.; Bespalov, A. Restoration of home cage activity in Tg2576 mice by immunotherapy with the Ab-oligomer selective antibody A-887755. Alzheimer's Dement. 2011, 7, S772.
-
(2011)
Alzheimer's Dement.
, vol.7
-
-
Relo, A.1
Barghorn, S.2
Ebert, U.3
Hillen, H.4
Gross, G.5
Schoemaker, H.6
Bespalov, A.7
-
57
-
-
84989182917
-
Perspectives on future Alzheimer's therapies: Amyloid-ssprotofibrils-a new target for immunotherapy with BAN2401 in Alzheimer's disease
-
Lannfelt, L.; Moller, C.; Basun, H.; Osswald, G.; Sehlin, D.; Satlin, A.; Logovinsky, V.; Gellerfors, P. Perspectives on future Alzheimer's therapies: amyloid-ssprotofibrils-a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimer's Res. Ther. 2014, 6, 16-24.
-
(2014)
Alzheimer's Res. Ther.
, vol.6
, pp. 16-24
-
-
Lannfelt, L.1
Moller, C.2
Basun, H.3
Osswald, G.4
Sehlin, D.5
Satlin, A.6
Logovinsky, V.7
Gellerfors, P.8
-
58
-
-
62049083728
-
Directin vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers
-
Meli, G.; Visintin, M.; Cannistraci, I.; Cattaneo, A. Directin vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. J. Mol. Biol. 2009, 387, 584-606.
-
(2009)
J. Mol. Biol.
, vol.387
, pp. 584-606
-
-
Meli, G.1
Visintin, M.2
Cannistraci, I.3
Cattaneo, A.4
-
59
-
-
84901502442
-
Conformational targeting of intracellular ACColigomers demonstrates their pathological oligomerization inside the endoplasmic reticulum
-
Meli, G.; Lecci, A.; Manca, A.; Krako, N.; Albertini, V.; Benussi, L.; Ghidoni, R.; Cattaneo, A. Conformational targeting of intracellular ACColigomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. Nat. Commun. 2014, 3, 3867-3878.
-
(2014)
Nat. Commun.
, vol.3
, pp. 3867-3878
-
-
Meli, G.1
Lecci, A.2
Manca, A.3
Krako, N.4
Albertini, V.5
Benussi, L.6
Ghidoni, R.7
Cattaneo, A.8
-
60
-
-
84870607253
-
Rational design of potent domain antibody inhibitors of amyloid fibril assembly
-
Ladiwala, A.R.A.; Bhattacharya, M.; Perchiacca, J.M.; Cao, P.; Raleigh, D.P.; Abedini, A.; Schmidt, A.M.; Varkey, J.; Langen, R.; Tessier, P.M. Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc. Natl. Acad. Sci. USA 2012, 109, 19965-19970.
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 19965-19970
-
-
Ladiwala, A.R.A.1
Bhattacharya, M.2
Perchiacca, J.M.3
Cao, P.4
Raleigh, D.P.5
Abedini, A.6
Schmidt, A.M.7
Varkey, J.8
Langen, R.9
Tessier, P.M.10
-
62
-
-
84894366258
-
P.; Tortelli, R.; Santamato, A.; Logroscino, G.; Amyloidbased immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward
-
Panza, F; Solfrizzi, V.; Imbimbo, B. P.; Tortelli, R.; Santamato, A.; Logroscino, G.; Amyloidbased immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev. Clin. Immunol. 2014, 10, 405-419.
-
(2014)
Expert Rev. Clin. Immunol.
, vol.10
, pp. 405-419
-
-
Panza, F.1
Solfrizzi, V.2
Imbimbo, B.3
-
63
-
-
8044226013
-
Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation
-
Lopera, F.; Ardilla, A.; Martínez, A.; Madrigal, L.; Arango-Viana, J.; Lemere, C.A.; Arango- Lasprilla, J.; Hincapié, L.; Arcos-Burgos, M.; Ossa, J.E.; et al Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation. JAMA 1997, 277, 793-799.
-
(1997)
JAMA
, vol.277
, pp. 793-799
-
-
Lopera, F.1
Ardilla, A.2
Martínez, A.3
Madrigal, L.4
Arango-Viana, J.5
Lemere, C.A.6
Arango-Lasprilla, J.7
Hincapié, L.8
Arcos-Burgos, M.9
Ossa, J.E.10
-
64
-
-
84885649629
-
Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: End of beginning or beginning of end?
-
Li, Y.; Liu, Y.; Wang, Z.; Jiang, Y. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Expert Rev. Clin. Immunol. 2013, 13, 1515-1522.
-
(2013)
Expert Rev. Clin. Immunol.
, vol.13
, pp. 1515-1522
-
-
Li, Y.1
Liu, Y.2
Wang, Z.3
Jiang, Y.4
-
65
-
-
0036085702
-
Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals
-
Weksler, M.E.; Relkin, N.; Turkenich, R.; LaRusse, S.; Zhou, L.; Szabo, P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002, 37, 943-948.
-
(2002)
Exp. Gerontol.
, vol.37
, pp. 943-948
-
-
Weksler, M.E.1
Relkin, N.2
Turkenich, R.3
LaRusse, S.4
Zhou, L.5
Szabo, P.6
-
66
-
-
68949169046
-
IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders
-
Fillit, H.; Hess, G.; Hill, J.; Bonnet, P.; Toso, C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009, 73, 180-185.
-
(2009)
Neurology
, vol.73
, pp. 180-185
-
-
Fillit, H.1
Hess, G.2
Hill, J.3
Bonnet, P.4
Toso, C.5
-
67
-
-
67749122581
-
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease
-
Britschgi, M.; Olin, C.E.; Johns, H.T.; Takeda-Uchimura, Y.; LeMieux, M.C.; Rufibach, K.; Rajadas, J.; Zhang, H.; Tomooka, B.; Robinson, W.H.; et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2009, 106, 12145-12150.
-
(2009)
Proc. Natl. Acad. Sci. USA
, vol.106
, pp. 12145-12150
-
-
Britschgi, M.1
Olin, C.E.2
Johns, H.T.3
Takeda-Uchimura, Y.4
LeMieux, M.C.5
Rufibach, K.6
Rajadas, J.7
Zhang, H.8
Tomooka, B.9
Robinson, W.H.10
-
68
-
-
84881340502
-
Naturally occurring autoantibodies interfere with [beta]-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer/'s disease 24h after single treatment
-
Mengel, D.; Roskam, S.; Neff, F.; Balakrishnan, K.; Deuster, O.; Gold, M.; Oertel, W.H.; Bacher, M.; Bach, J.-P.; Dodel, R. Naturally occurring autoantibodies interfere with [beta]-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer/'s disease 24h after single treatment. Transl. Psychiat. 2013, 3, 233-243.
-
(2013)
Transl. Psychiat.
, vol.3
, pp. 233-243
-
-
Mengel, D.1
Roskam, S.2
Neff, F.3
Balakrishnan, K.4
Deuster, O.5
Gold, M.6
Oertel, W.H.7
Bacher, M.8
Bach, J.-P.9
Dodel, R.10
-
69
-
-
79955758133
-
Naturally occurring autoantibodies against beta-amyloid: Investigating their role in transgenic animal and in vitro models of Alzheimer's disease
-
Dodel, R.; Balakrishnan, K.; Keyvani, K.; Deuster, O.; Neff, F.; Andrei-Selmer, L.C.; Roskam, S.; Stuer, C.; Al-Abed, Y.; Noelker, C.; et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J. Neurosci. 2011, 31, 5847-5854.
-
(2011)
J. Neurosci.
, vol.31
, pp. 5847-5854
-
-
Dodel, R.1
Balakrishnan, K.2
Keyvani, K.3
Deuster, O.4
Neff, F.5
Andrei-Selmer, L.C.6
Roskam, S.7
Stuer, C.8
Al-Abed, Y.9
Noelker, C.10
-
70
-
-
0027361281
-
Microtubule associated protein tau: Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease
-
Kfpke, E.; Tung, Y.C.; Shaikh, S.; Alonso, A.C.; Iqbal, K.; Grundke-Iqbal, I. Microtubule associated protein tau: abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 1993, 268, 24374-24384.
-
(1993)
J. Biol. Chem.
, vol.268
, pp. 24374-24384
-
-
Kfpke, E.1
Tung, Y.C.2
Shaikh, S.3
Alonso, A.C.4
Iqbal, K.5
Grundke-Iqbal, I.6
-
71
-
-
0036937699
-
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease
-
Augustinack, J.C.; Schneider, A.; Mandelkow, E.M.; Hyman, B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103, 26-35.
-
(2002)
Acta Neuropathol.
, vol.103
, pp. 26-35
-
-
Augustinack, J.C.1
Schneider, A.2
Mandelkow, E.M.3
Hyman, B.T.4
-
72
-
-
84858965241
-
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease
-
Lasagna-Reeves, C.A.; Castillo-Carranza, D.L.; Sengupta, U.; Sarmiento, J.; Troncoso, J.; Jackson, G.R.; Kayed, R. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012, 26, 1946-1959.
-
(2012)
FASEB J.
, vol.26
, pp. 1946-1959
-
-
Lasagna-Reeves, C.A.1
Castillo-Carranza, D.L.2
Sengupta, U.3
Sarmiento, J.4
Troncoso, J.5
Jackson, G.R.6
Kayed, R.7
-
73
-
-
54249156984
-
Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
-
Sigurdsson, E.M. Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies. J. Alzheimers Dis. 2008, 15, 157-168.
-
(2008)
J. Alzheimers Dis
, vol.15
, pp. 157-168
-
-
Sigurdsson, E.M.1
-
74
-
-
84865607168
-
Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model
-
Krishnamurthy, P.K.; Deng, Y.; Sigurdsson, E.M. Mechanistic studies of antibody-mediated clearance of Tau aggregates using an ex vivo brain slice model. Front. Psychiat. 2011, 2, 59.
-
(2011)
Front. Psychiat.
, vol.2
, pp. 59
-
-
Krishnamurthy, P.K.1
Deng, Y.2
Sigurdsson, E.M.3
-
75
-
-
84887837879
-
Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology
-
Gu, J.; Congdon, E.E.; Sigurdsson, E.M. Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology. J. Biol. Chem. 2013, 288, 33081-33091.
-
(2013)
J. Biol. Chem.
, vol.288
, pp. 33081-33091
-
-
Gu, J.1
Congdon, E.E.2
Sigurdsson, E.M.3
-
76
-
-
84890282160
-
Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fc_ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance
-
Congdon, E.E.; Gu, J.; Sait, H.B.R.; Sigurdsson, E.M. Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fc_ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance. J. Biol. Chem. 2013, 288, 35452-35465.
-
(2013)
J. Biol. Chem.
, vol.288
, pp. 35452-35465
-
-
Congdon, E.E.1
Gu, J.2
Sait, H.B.R.3
Sigurdsson, E.M.4
-
77
-
-
84927662307
-
Tau-based therapeutic approaches for Alzheimer's disease- A mini-review
-
Boutajangout, A.; Wisniewski, T. Tau-based therapeutic approaches for Alzheimer's disease- A mini-review. Gerontology 2014, 60, 381-385.
-
(2014)
Gerontology
, vol.60
, pp. 381-385
-
-
Boutajangout, A.1
Wisniewski, T.2
-
78
-
-
80855148339
-
Opposing roles of microglial activation in amyloid depositing and tau depositing transgenic mice
-
Morgan, D.; Lee, D.; Brownlow, M.; Selenica, M.-L.; Reid, P.; Alvarez, J.; Gordon, M.N. Opposing roles of microglial activation in amyloid depositing and tau depositing transgenic mice. Neurodegen. Dis. 2011, 8 (Suppl. 1), 1.
-
(2011)
Neurodegen. Dis.
, vol.8
, pp. 1
-
-
Morgan, D.1
Lee, D.2
Brownlow, M.3
Selenica, M.-L.4
Reid, P.5
Alvarez, J.6
Gordon, M.N.7
-
79
-
-
84876908676
-
Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity
-
d'Abramo, C.; Acker, C.M.; Jimenez, H.T.; Davies, P. Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity. PLoS One 2013, 8, e62402.
-
(2013)
PLoS One
, vol.8
-
-
d'Abramo, C.1
Acker, C.M.2
Jimenez, H.T.3
Davies, P.4
-
80
-
-
67649273927
-
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
-
Frost, B.; Jacks, R.L.; Diamond, M.I. Propagation of Tau Misfolding from the Outside to the Inside of a Cell. J. Biol. Chem. 2009, 284, 12845-12852.
-
(2009)
J. Biol. Chem.
, vol.284
, pp. 12845-12852
-
-
Frost, B.1
Jacks, R.L.2
Diamond, M.I.3
-
81
-
-
79955441814
-
Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
-
Guo, J.L.; Lee, V.M. Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles. J. Biol. Chem. 2011, 286, 15317-15331.
-
(2011)
J. Biol. Chem.
, vol.286
, pp. 15317-15331
-
-
Guo, J.L.1
Lee, V.M.2
-
82
-
-
84857275902
-
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
-
de Calignon, A.; Polydoro, M.; Suarez-Calvet, M.; William, C.; Adamowicz, D.H.; Kopeikina, K.J.; Pitstick, R.; Sahara, N.; Ashe, K.H.; Carlson, G.A.; et al. Propagation of Tau Pathology in a Model of Early Alzheimer's Disease. Neuron 2012, 73, 685-697.
-
(2012)
Neuron
, vol.73
, pp. 685-697
-
-
de Calignon, A.1
Polydoro, M.2
Suarez-Calvet, M.3
William, C.4
Adamowicz, D.H.5
Kopeikina, K.J.6
Pitstick, R.7
Sahara, N.8
Ashe, K.H.9
Carlson, G.A.10
-
83
-
-
84885783467
-
Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition
-
Yanamandra, K.; Kfoury, N.; Jiang, H.; Mahan, T.E.; Ma, S.; Maloney, S.E.; Wozniak, D.F.; Diamond, M.I.; Holtzman, D.M. Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo. Neuron 2013, 80, 402-414.
-
(2013)
In Vivo. Neuron
, vol.80
, pp. 402-414
-
-
Yanamandra, K.1
Kfoury, N.2
Jiang, H.3
Mahan, T.E.4
Ma, S.5
Maloney, S.E.6
Wozniak, D.F.7
Diamond, M.I.8
Holtzman, D.M.9
-
84
-
-
84861758226
-
Trans-cellular propagation of Tau aggregation by fibrillar species
-
Kfoury, N.; Holmes, B.B.; Jiang, H.; Holtzman, D.M.; Diamond, M.I. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 2012, 287, 19440-19451.
-
(2012)
J. Biol. Chem.
, vol.287
, pp. 19440-19451
-
-
Kfoury, N.1
Holmes, B.B.2
Jiang, H.3
Holtzman, D.M.4
Diamond, M.I.5
-
85
-
-
84896269359
-
Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles
-
Castillo-Carranza, D.L.; Sengupta, U.; Guerrero-Muñoz, M.J.; Lasagna-Reeves, C.A.; Gerso, J.E.; Singh, G.; Estes, D.M.; Barrett, A.D.; Dineley, K.T.; Jackson, G.R.; et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 2014, 34, 4260-4272.
-
(2014)
J. Neurosci.
, vol.34
, pp. 4260-4272
-
-
Castillo-Carranza, D.L.1
Sengupta, U.2
Guerrero-Muñoz, M.J.3
Lasagna-Reeves, C.A.4
Gerso, J.E.5
Singh, G.6
Estes, D.M.7
Barrett, A.D.8
Dineley, K.T.9
Jackson, G.R.10
-
86
-
-
84877580799
-
Immunotherapy for neurodegenerative diseases: Focus on 8-synucleinopathies
-
Valera, E.; Masliah, E. Immunotherapy for neurodegenerative diseases: Focus on 8-synucleinopathies. Pharmacol. Therap. 2013, 138, 311-322.
-
(2013)
Pharmacol. Therap.
, vol.138
, pp. 311-322
-
-
Valera, E.1
Masliah, E.2
-
87
-
-
0025863618
-
Neuropathological stageing of Alzheimer-related changes
-
Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239-259.
-
(1991)
Acta Neuropathol.
, vol.82
, pp. 239-259
-
-
Braak, H.1
Braak, E.2
-
88
-
-
85005896337
-
The prion hypothesis in Parkinson's disease: Braak to the future
-
Visanji, N.P.; Brooks, P.L.; Hazrati, L.; Lang, A.E. The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol. Commun. 2013, 1, 2.
-
(2013)
Acta Neuropathol. Commun
, vol.1
, pp. 2
-
-
Visanji, N.P.1
Brooks, P.L.2
Hazrati, L.3
Lang, A.E.4
-
89
-
-
79551519276
-
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells
-
Hansen, C.; Angot, E.; Bergström, A.; Steiner, J.A.; Pieri, L.; Paul, G.; Outeiro, T.F.; Melki, R.; Kallunki, P.; Fog, K.; et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 2011, 121, 715-725.
-
(2011)
J. Clin. Invest
, vol.121
, pp. 715-725
-
-
Hansen, C.1
Angot, E.2
Bergström, A.3
Steiner, J.A.4
Pieri, L.5
Paul, G.6
Outeiro, T.F.7
Melki, R.8
Kallunki, P.9
Fog, K.10
-
90
-
-
79960285197
-
Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat
-
Kordower, J.H.; Dodiya, H.B.; Kordower, A.M.; Terpstra, B.; Paumier, K.; Madhavan, L.; Sortwell, C.; Steece-Collier, K.; Collier, T.J. Transfer of host-derived α synuclein to grafted dopaminergic neurons in rat. Neurobiol. Dis. 2011, 43, 552-557.
-
(2011)
Neurobiol. Dis
, vol.43
, pp. 552-557
-
-
Kordower, J.H.1
Dodiya, H.B.2
Kordower, A.M.3
Terpstra, B.4
Paumier, K.5
Madhavan, L.6
Sortwell, C.7
Steece-Collier, K.8
Collier, T.J.9
-
91
-
-
80053613574
-
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death
-
Volpicelli-Daley, L.A.; Luk, K.L.; Patel, T.P; Tanik, S.A.; Riddle, D.M.; Stieber, A.; Meany, D.F.; Trojanowski, J.Q.; Lee, V.M.-Y. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011, 72, 57-71.
-
(2011)
Neuron
, vol.72
, pp. 57-71
-
-
Volpicelli-Daley, L.A.1
Luk, K.L.2
Patel, T.P.3
Tanik, S.A.4
Riddle, D.M.5
Stieber, A.6
Meany, D.F.7
Trojanowski, J.Q.8
Lee, V.M.-Y.9
-
92
-
-
69149089854
-
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
-
Desplats, P.; Lee, H.J.; Bae, E.J.; Patrick, C.; Rockenstein, E.; Crews, L.; Spencer, B.; Masliah, E.; Lee, S.J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl. Acad. Sci. USA 2009, 106, 13010-13015.
-
(2009)
Proc. Natl. Acad. Sci. USA
, vol.106
, pp. 13010-13015
-
-
Desplats, P.1
Lee, H.J.2
Bae, E.J.3
Patrick, C.4
Rockenstein, E.5
Crews, L.6
Spencer, B.7
Masliah, E.8
Lee, S.J.9
-
93
-
-
84863433677
-
Prion-like acceleration of a synucleinopathy in a transgenic mouse model
-
Mougenot, A.L.; Nicot, S.; Bencsik, A.; Morignat, E.; Verchere, J.; Lakhdar, L.; Legastelios, S.; Baron, T. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 2012, 33, 2225-2228.
-
(2012)
Neurobiol. Aging
, vol.33
, pp. 2225-2228
-
-
Mougenot, A.L.1
Nicot, S.2
Bencsik, A.3
Morignat, E.4
Verchere, J.5
Lakhdar, L.6
Legastelios, S.7
Baron, T.8
-
94
-
-
84862609075
-
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice
-
Luk, K.C.; Kehm, V.M.; Zhang, B.; O'Brien, P.; Trojanowski, J.Q.; Lee, V.M. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 2012, 209, 975-986.
-
(2012)
J. Exp. Med
, vol.209
, pp. 975-986
-
-
Luk, K.C.1
Kehm, V.M.2
Zhang, B.3
O'Brien, P.4
Trojanowski, J.Q.5
Lee, V.M.6
-
95
-
-
36248965693
-
Role of different regions of 9-synuclein in the assembly of fibrils
-
Qin, Z.; Hu, D.; Han, S.; Hong, D.P.; Fink, A.L. Role of different regions of 9-synuclein in the assembly of fibrils. Biochemistry 2007, 46, 13322-13330.
-
(2007)
Biochemistry
, vol.46
, pp. 13322-13330
-
-
Qin, Z.1
Hu, D.2
Han, S.3
Hong, D.P.4
Fink, A.L.5
-
96
-
-
84903441419
-
α-synuclein immunotherapy blocks uptake and template propagation of misfolded α-synuclein and neurodegeneration
-
Tran, H.T.; Chung, C.H.; Iba, M.; Zhang, B.; Trojanowski, J.Q.; Luk, K.C.; Lee, V.M.Y. α-synuclein immunotherapy blocks uptake and template propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. 2014, 7, 2054-2065.
-
(2014)
Cell Rep.
, vol.7
, pp. 2054-2065
-
-
Tran, H.T.1
Chung, C.H.2
Iba, M.3
Zhang, B.4
Trojanowski, J.Q.5
Luk, K.C.6
Lee, V.M.Y.7
-
97
-
-
79955757052
-
Passive immunisation reduces behavioural and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease
-
Masliah, E.; Rockenstein, E.; Mante, M.; Crews, L.; Spencer, B.; Adame, A.; Patrick, C.; Trejo, M.; Ubhi, K.; Rohn, T.T.; et al. Passive immunisation reduces behavioural and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011, 6, e19338.
-
(2011)
PLoS One
, vol.6
-
-
Masliah, E.1
Rockenstein, E.2
Mante, M.3
Crews, L.4
Spencer, B.5
Adame, A.6
Patrick, C.7
Trejo, M.8
Ubhi, K.9
Rohn, T.T.10
-
98
-
-
0035815664
-
Evidence for a partially folded intermediate in alpha-synuclein fibril formation
-
Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 2001, 276, 10737-10744.
-
(2001)
J. Biol. Chem.
, vol.276
, pp. 10737-10744
-
-
Uversky, V.N.1
Li, J.2
Fink, A.L.3
-
99
-
-
84879419913
-
Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognise brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation
-
Fagerqvist, T.; Lindstrom, V.; Nordstrom, E.; Lord, A.; Tucker, S.M.E.; Su, X.; Sahlin, C.; Kasrayan, A.; Andersson, J.; Welander, H.; et al. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognise brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem. 2013, 126, 131-144.
-
(2013)
J. Neurochem.
, vol.126
, pp. 131-144
-
-
Fagerqvist, T.1
Lindstrom, V.2
Nordstrom, E.3
Lord, A.4
Tucker, S.M.E.5
Su, X.6
Sahlin, C.7
Kasrayan, A.8
Andersson, J.9
Welander, H.10
-
100
-
-
66449097646
-
Detecting morphologically distinct oligomeric forms of α-synuclein
-
Emadi, S.; Kasturirangan, S.; Wang, M.S.; Schulz, P.; Sierks, M. Detecting morphologically distinct oligomeric forms of α-synuclein. J. Biol. Chem. 2009, 284, 11048-11058.
-
(2009)
J. Biol. Chem.
, vol.284
, pp. 11048-11058
-
-
Emadi, S.1
Kasturirangan, S.2
Wang, M.S.3
Schulz, P.4
Sierks, M.5
-
101
-
-
84902177925
-
Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice
-
Lindstrom, V.; Fagerqvist, T.; Nordstrom, E.; Eriksson, F.; Lord, A.; Tucker, S.M.E.; Andersson, J.; Johannesson, M.; Schell, P.J.; Moller, C.; et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol. Dis. 2014, 69, 134-143.
-
(2014)
Neurobiol. Dis.
, vol.69
, pp. 134-143
-
-
Lindstrom, V.1
Fagerqvist, T.2
Nordstrom, E.3
Eriksson, F.4
Lord, A.5
Tucker, S.M.E.6
Andersson, J.7
Johannesson, M.8
Schell, P.J.9
Moller, C.10
-
102
-
-
84901985544
-
Intracellular processing of disease-associated α-synuclein in the human brain suggest prion-like cell-to-cell spread
-
Kovacs, G.G.; Breydo, L.; Green, R.; Kis, V.; Puska, G.; Lorincz, P.; Perju-Dumbrava, L.; Giera, R.; Pirker, W.; Lutz, M.; et al. Intracellular processing of disease-associated α-synuclein in the human brain suggest prion-like cell-to-cell spread. Neurobiol. Dis. 2014, 69, 76-92.
-
(2014)
Neurobiol. Dis.
, vol.69
, pp. 76-92
-
-
Kovacs, G.G.1
Breydo, L.2
Green, R.3
Kis, V.4
Puska, G.5
Lorincz, P.6
Perju-Dumbrava, L.7
Giera, R.8
Pirker, W.9
Lutz, M.10
-
103
-
-
77956885443
-
Structure and properties of a complex of α-synuclein and single-domain camelid antibody
-
De Genst, E.J.; Guilliams, T.; Wellens, J.; O'Day, E.M.; Waudby, C.A.; Meehan, S.; Dumoulin, M.; Hsu, A.D.; Cremades, N.; Verschueren, K.H.G.; et al. Structure and properties of a complex of α-synuclein and single-domain camelid antibody. J. Biol. Chem. 2010, 402, 326-343.
-
(2010)
J. Biol. Chem.
, vol.402
, pp. 326-343
-
-
De Genst, E.J.1
Guilliams, T.2
Wellens, J.3
O'Day, E.M.4
Waudby, C.A.5
Meehan, S.6
Dumoulin, M.7
Hsu, A.D.8
Cremades, N.9
Verschueren, K.H.G.10
-
104
-
-
33846817163
-
Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity
-
Volles, M.J.; Lansbury, P.T., Jr. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J. Mol. Biol. 2007, 366, 1510-1522.
-
(2007)
J. Mol. Biol.
, vol.366
, pp. 1510-1522
-
-
Volles, M.J.1
Lansbury, P.T.2
-
105
-
-
77958449984
-
1-Synuclein: Membrane interactions and toxicity in Parkinson's disease
-
Auluck, P.K.; Caraveo, G.; Lindquist, S. 1-Synuclein: membrane interactions and toxicity in Parkinson's disease. Ann. Rev. Cell Develop. Biol. 2010, 26, 211-233.
-
(2010)
Ann. Rev. Cell Develop. Biol.
, vol.26
, pp. 211-233
-
-
Auluck, P.K.1
Caraveo, G.2
Lindquist, S.3
-
106
-
-
10344257196
-
A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein
-
Zhou, C.; Wmadi, S.; Sierks, M.R.; Messer, A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 2004, 10, 1023-1031.
-
(2004)
Mol. Ther.
, vol.10
, pp. 1023-1031
-
-
Zhou, C.1
Wmadi, S.2
Sierks, M.R.3
Messer, A.4
-
107
-
-
39649109675
-
An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity
-
Lynch, S.M.; Zhou, C.; Messer, A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 2008, 377, 136-147.
-
(2008)
J. Mol. Biol.
, vol.377
, pp. 136-147
-
-
Lynch, S.M.1
Zhou, C.2
Messer, A.3
-
108
-
-
0027480960
-
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
-
MacDonald, M.E.; Ambrose, C.M.; Duyao, M.P.; Myers, R.H.; Lin, C.; Srinidhi, L.; Barnes, G.; Taylor, S.A.; James, M.; Groot, N.; et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72, 971-983.
-
(1993)
Cell
, vol.72
, pp. 971-983
-
-
McDonald, M.E.1
Ambrose, C.M.2
Duyao, M.P.3
Myers, R.H.4
Lin, C.5
Srinidhi, L.6
Barnes, G.7
Taylor, S.A.8
James, M.9
Groot, N.10
-
109
-
-
84860692601
-
Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins
-
Butler, D.C.; McLear, J.A.; Messer, A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog. Neurobiol. 2012, 97, 190-204.
-
(2012)
Prog. Neurobiol.
, vol.97
, pp. 190-204
-
-
Butler, D.C.1
McLear, J.A.2
Messer, A.3
-
110
-
-
82555176538
-
A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition
-
Schiefner, A.; Chatwell, L.; Korner, J.; Neumaier, I.; Colby, D.W.; Volkmer, R.; Wittrup, K.D.; Skerra, A. A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J. Mol. Biol. 2011, 414, 337-355.
-
(2011)
J. Mol. Biol.
, vol.414
, pp. 337-355
-
-
Schiefner, A.1
Chatwell, L.2
Korner, J.3
Neumaier, I.4
Colby, D.W.5
Volkmer, R.6
Wittrup, K.D.7
Skerra, A.8
-
111
-
-
54049111928
-
Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity
-
Southwell, A.L.; Khoshnan, A.; Dunn, D.E.; Bugg, C.W.; Lo, D.C.; Patterson, P.H. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J. Neurosc. 2008, 28, 9013-9020.
-
(2008)
J. Neurosc.
, vol.28
, pp. 9013-9020
-
-
Southwell, A.L.1
Khoshnan, A.2
Dunn, D.E.3
Bugg, C.W.4
Lo, D.C.5
Patterson, P.H.6
-
112
-
-
0035836675
-
Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease
-
Lecerf, J.M.; Shirley, T.L.; Zhu, Q.; Kazantsev, A.; Amersdorfer, P.; Housman, D.E.; Messer, A.; Huston, J.S. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 2001, 98, 4764-4769.
-
(2001)
Proc. Natl. Acad. Sci. USA
, vol.98
, pp. 4764-4769
-
-
Lecerf, J.M.1
Shirley, T.L.2
Zhu, Q.3
Kazantsev, A.4
Amersdorfer, P.5
Housman, D.E.6
Messer, A.7
Huston, J.S.8
-
113
-
-
17544377783
-
A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease
-
Miller, T.W.; Zhou, C.; Gines, S.; MacDonald, M.E.; Mazarakis, N.D.; Bates, G.P.; Huston, J.S.; Messer, A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol. Dis. 2005, 19, 47-56.
-
(2005)
Neurobiol. Dis.
, vol.19
, pp. 47-56
-
-
Miller, T.W.1
Zhou, C.2
Gines, S.3
McDonald, M.E.4
Mazarakis, N.D.5
Bates, G.P.6
Huston, J.S.7
Messer, A.8
-
114
-
-
84055182535
-
Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments
-
Butler, D.C.; Messer, A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One 2011, 6, e29199.
-
(2011)
PLoS One
, vol.6
-
-
Butler, D.C.1
Messer, A.2
-
115
-
-
0037154165
-
Effects of intracellular expression of antihuntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity
-
Khoshnan, A.; Ko, J.; Patterson, P.H. Effects of intracellular expression of antihuntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA 2002, 99, 1002-1007.
-
(2002)
Proc. Natl. Acad. Sci. USA
, vol.99
, pp. 1002-1007
-
-
Khoshnan, A.1
Ko, J.2
Patterson, P.H.3
-
116
-
-
62949091373
-
Autophagy: A lysosomal degradation pathway with a central role in health and disease
-
Eskelinen, E.; Saftig, P. Autophagy: A lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta 2009, 1793, 664-673.
-
(2009)
Biochim. Biophys. Acta
, vol.1793
, pp. 664-673
-
-
Eskelinen, E.1
Saftig, P.2
-
117
-
-
79551645514
-
Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1
-
Southwell, A.L.; Bugg, C.W.; Kaltenbach, L.S.; Dunn, D.E.; Butland, S.; Weiss, A.; Paganetti, P.; Lo, D.C.; Patterson, P.H. Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS One 2011, 6, e16676.
-
(2011)
PLoS One
, vol.6
-
-
Southwell, A.L.1
Bugg, C.W.2
Kaltenbach, L.S.3
Dunn, D.E.4
Butland, S.5
Weiss, A.6
Paganetti, P.7
Lo, D.C.8
Patterson, P.H.9
-
118
-
-
57549096688
-
The POM Monoclonals: A Comprehensive Set of Antibodies to Non-Overlapping Prion Protein Epitopes
-
Polymenidou, M.; Moos, R.; Scott, M.; Sigurdson, C.; Shi, Y.; Yajima, B.; Hafner-Bratkovic, I.; Jerala, R.; Hornemann, S.; Wuthrich, K.; et al. The POM Monoclonals: A Comprehensive Set of Antibodies to Non-Overlapping Prion Protein Epitopes. PLoS One 2008, 3, e3872.
-
(2008)
PLoS One
, vol.3
-
-
Polymenidou, M.1
Moos, R.2
Scott, M.3
Sigurdson, C.4
Shi, Y.5
Yajima, B.6
Hafner-Bratkovic, I.7
Jerala, R.8
Hornemann, S.9
Wuthrich, K.10
-
119
-
-
84883742582
-
The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein
-
Sonati, T.; Reimann, R.R.; Falsig, J.; Baral, P.K.; O'Connor, T.; Hornemann, S.; Yaganoglu, S.; Li, B.; Herrmann, U.S.; Wieland, B.; et al. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature 2013, 501, 102-106.
-
(2013)
Nature
, vol.501
, pp. 102-106
-
-
Sonati, T.1
Reimann, R.R.2
Falsig, J.3
Baral, P.K.4
O'Connor, T.5
Hornemann, S.6
Yaganoglu, S.7
Li, B.8
Herrmann, U.S.9
Wieland, B.10
-
120
-
-
84892960113
-
Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody
-
Abskharon, R.N.N.; Giachin, G.; Wohlkonig, A.; Soror. S.H.; Pardon, E.; Legname. G.; Steyaert, J. Probing the N-terminal β-sheet conversion in the crystal structure of the human prion protein bound to a nanobody. J. Am. Chem. Soc. 2014, 136, 937-944.
-
(2014)
J. Am. Chem. Soc.
, vol.136
, pp. 937-944
-
-
Abskharon, R.N.N.1
Giachin, G.2
Wohlkonig, A.3
Soror, S.H.4
Pardon, E.5
Legname, G.6
Steyaert, J.7
-
121
-
-
84859741481
-
Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity
-
Wei, X.; Roettger, Y.; Tan, B.; He, Y.; Dodel, R.; Hampel, H.; Wei, G.; Haney, J.; Gu, H.; Johnstone, B.H.; et al. Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity. J. Biol. Chem. 2012, 287, 12858-12866.
-
(2012)
J. Biol. Chem.
, vol.287
, pp. 12858-12866
-
-
Wei, X.1
Roettger, Y.2
Tan, B.3
He, Y.4
Dodel, R.5
Hampel, H.6
Wei, G.7
Haney, J.8
Gu, H.9
Johnstone, B.H.10
-
122
-
-
84908252425
-
Prion protein-specific antibodies-development, modes of action and therapeutics applications
-
Rovis, T.L.; Legname, G. Prion protein-specific antibodies-development, modes of action and therapeutics applications. Viruses 2014, 6, 3719-3737.
-
(2014)
Viruses
, vol.6
, pp. 3719-3737
-
-
Rovis, T.L.1
Legname, G.2
-
123
-
-
0035812752
-
Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies
-
Heppner, F.L.; Musahl, C.; Arrighi, I.; Klein, M.A.; Rulicke, T.; Oesch, B.; Zinkernagel, R.M.; Kalinke, U.; Aguzzi, A. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001, 294, 178-182.
-
(2001)
Science
, vol.294
, pp. 178-182
-
-
Heppner, F.L.1
Musahl, C.2
Arrighi, I.3
Klein, M.A.4
Rulicke, T.5
Oesch, B.6
Zinkernagel, R.M.7
Kalinke, U.8
Aguzzi, A.9
-
124
-
-
84866537161
-
Brain delivery of aav9 expressing an anti-prp monovalent antibody delays prion disease in mice
-
Moda, F.; Vimercati, C.; Campagnani, I.; Ruggerone, M.; Giaccone, G.; Morbin, M.; Zentilin, L.; Giacca, M.; Zucca, I.; Legname, G.; et al. Brain delivery of aav9 expressing an anti-prp monovalent antibody delays prion disease in mice. Prion 2012, 6, 383-390.
-
(2012)
Prion
, vol.6
, pp. 383-390
-
-
Moda, F.1
Vimercati, C.2
Campagnani, I.3
Ruggerone, M.4
Giaccone, G.5
Morbin, M.6
Zentilin, L.7
Giacca, M.8
Zucca, I.9
Legname, G.10
-
125
-
-
39849085645
-
CNS delivery of vectored prion-specific single-chain antibodies delays disease onset
-
Wuertzer, C.A.; Sullivan, M.A.; Qiu, X.; Federoff, H.J. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol. Ther. 2008, 16, 481-486.
-
(2008)
Mol. Ther.
, vol.16
, pp. 481-486
-
-
Wuertzer, C.A.1
Sullivan, M.A.2
Qiu, X.3
Federoff, H.J.4
-
126
-
-
84884241359
-
Gene-based antibody strategies for prion diseases
-
Cardinale, A.; Biocca, S. Gene-based antibody strategies for prion diseases. Int. J. Cell Biol. 2013, 2013, 710406.
-
(2013)
Int. J. Cell Biol.
, vol.2013
-
-
Cardinale, A.1
Biocca, S.2
-
127
-
-
84873085590
-
Recombinant single-chain antibody with the trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier
-
Skrlj, N.; Drevensek, G.; Hudoklin, S.; Romih, R.; Curin Serbec, V.; Dolinar, M. Recombinant single-chain antibody with the trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier. Appl. Biochem. Biotechnol. 2013, 169, 159-169.
-
(2013)
Appl. Biochem. Biotechnol.
, vol.169
, pp. 159-169
-
-
Skrlj, N.1
Drevensek, G.2
Hudoklin, S.3
Romih, R.4
Curin Serbec, V.5
Dolinar, M.6
-
128
-
-
84879968745
-
Developing therapeutic antibodies for neurodegenerative disease
-
Joy, Y.Y.; Watts, R.J. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 2013, 10, 459-472.
-
(2013)
Neurotherapeutics
, vol.10
, pp. 459-472
-
-
Joy, Y.Y.1
Watts, R.J.2
-
129
-
-
84863209627
-
Antibody-enabled small molecule drug discovery
-
Lawson, A.D.G. Antibody-enabled small molecule drug discovery. Nat. Rev. Drug Discov. 2012, 11, 519-525.
-
(2012)
Nat. Rev. Drug Discov.
, vol.11
, pp. 519-525
-
-
Lawson, A.D.G.1
-
130
-
-
67649805281
-
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions
-
Kokjohn, T.A.; Roher, E.A. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions. Alzheimer's Dement. 2009, 5, 340-347.
-
(2009)
Alzheimer's Dement.
, vol.5
, pp. 340-347
-
-
Kokjohn, T.A.1
Roher, E.A.2
-
131
-
-
35348932113
-
Transgenic animal models of neurodegenerative diseases and their application to treatment development
-
Rockenstein, E.; Crews, L.; Masliah, E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv. Drug Deliv. Rev. 2007, 59, 1093-1102.
-
(2007)
Adv. Drug Deliv. Rev.
, vol.59
, pp. 1093-1102
-
-
Rockenstein, E.1
Crews, L.2
Masliah, E.3
-
132
-
-
75649108560
-
Transgenic mouse models of Alzheimer's disease
-
Elder, G.A.; Gama Sosa, M.A.; De Gaspert, R. Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med. 2010, 77, 69-81.
-
(2010)
Mt. Sinai J. Med
, vol.77
, pp. 69-81
-
-
Elder, G.A.1
Gama Sosa, M.A.2
De Gaspert, R.3
-
133
-
-
77956056008
-
Animal models reveal role for tau phosphorylation in human disease
-
Götz, J.; Gladbach, A.; Pennanen, L.; van Eersel, J.; Schild A.; David, D.; Ittner, L.M. Animal models reveal role for tau phosphorylation in human disease. Biochim. Biophys. Acta 2010, 1802, 860-871.
-
(2010)
Biochim. Biophys. Acta
, vol.1802
, pp. 860-871
-
-
Götz, J.1
Gladbach, A.2
Pennanen, L.3
van Eersel, J.4
Schild, A.5
David, D.6
Ittner, L.M.7
|